

## Chemomab Therapeutics to Present at June Investor and Scientific Conferences

TEL AVIV, Israel, June 9, 2022 /PRNewswire/ -- [Chemomab Therapeutics Ltd.](#) (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that the company will participate in a number of investor and scientific conferences in June 2022.

### JMP Securities Life Sciences Conference:

**Date:** Thursday, June 16, 2022  
**Venue:** Lotte Palace Hotel, New York, NY USA  
**Format:** In-person live and webcast presentation; One-on-one meetings on June 16  
**Time:** 11:00 a.m. ET  
**Link:** <https://wsw.com/webcast/jmp54/cmmb/1657584>  
**Information:** <https://jmp-ls.ljfevents-rsvp.com/registration/>

A replay of the webcast will be available at the Investor section of Chemomab's website for at least 30 days.

### The Extracellular Matrix Pharmacology Congress

**Date:** June 23-25, 2022  
**Venue:** Tivoli Congress Center, Copenhagen, Denmark  
**Format:** Poster presentation: *CCL24 Inhibition by CM-101 Attenuates Extracellular Matrix and Fibrotic Biomarkers in Both Patients and Experimental Murine Models*, Abstract ID:155  
**Time:** Poster Session 1, June 23 from 13:00 - 14:15 CET  
**Presenter:** Udi Gluschnaider, PhD, Chemomab Project Lead  
**Information:** [ECM Congress \(ecm-congress.org\)](http://ecm-congress.org)

A copy of the poster will be available at the R&D section of Chemomab's website starting on June 23, 2022.

### EASL: The International Liver Congress™ 2022

**Date:** June 22-26, 2022  
**Venue:** ExCeL London, London, UK, and virtual  
**Format:** Oral poster presentation: *Combination of whole liver single cell RNA sequencing and spatial transcriptomics reveals specific cell sub-populations and pathways regulated by CCL24*, Abstract Identifier: OS02  
**Presenter:** Raanan Greenman, PhD, Chemomab Project Lead  
**Time:** June 23, 2022, 16:45 CET  
**Session:** Immune-mediated and cholestatic: Experimental and pathophysiology  
**Information:** <https://easl.eu/event/international-liver-congress-2022/>

The presentation will be available at the R&D section of Chemomab's website starting on June 24, 2022

In addition, Chemomab's business development team members will be in San Diego, California June 13-16, 2022, participating in the **BIO International Convention's One-on-One Partnering™** event. Registered attendees can click [here](#) to log in and schedule a meeting with Chemomab.

### About Chemomab Therapeutics Ltd.

Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to begin in late 2022. For more information, visit [chemomab.com](http://chemomab.com).

### Contacts:

#### Investor Relations:

Irina Koffler  
LifeSci Advisors, LLC  
Phone: +1 917-734-7387  
[ir@chemomab.com](mailto:ir@chemomab.com)

#### Media:

Barbara Lindheim  
Chemomab Therapeutics  
Consulting Vice President,  
Investor & Public Relations,

Strategic Communications  
Phone: +1 917-355-9234  
[barbara@chemomab.com](mailto:barbara@chemomab.com)

SOURCE Chemomab Therapeutics, Ltd.

---